Premium
Cytoreductive surgery and HIPEC offers similar outcomes in patients with rectal peritoneal metastases compared to colon cancer patients: a matched case control study
Author(s) -
Simkens Geert A.,
van Oudheusden Thijs R.,
Braam Hidde J.,
Wiezer Marinus J.,
Nienhuijs Simon W.,
Rutten Harm J.,
van Ramshorst Bert,
de Hingh Ignace H.
Publication year - 2016
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.24169
Subject(s) - medicine , colorectal cancer , hyperthermic intraperitoneal chemotherapy , stage (stratigraphy) , surgery , gastroenterology , cytoreductive surgery , cancer , ovarian cancer , paleontology , biology
Background & Objectives The effect of cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with rectal peritoneal metastases (PM) is unclear. This case‐control study aims to assess the results of cytoreduction and HIPEC in patients with rectal PM compared to colon PM patients. Methods Colorectal PM patients treated with complete macroscopic cytoreduction and HIPEC were included. Two colon cancer patients were case‐matched for each rectal cancer patient, based on prognostic factors (T stage, N stage, histology type, and extent of PM). Short‐ and long‐term outcomes were compared between both groups. Results From 317 patients treated with complete macroscopic cytoreduction and HIPEC, 29 patients (9.1%) had rectal PM. Fifty‐eight colon cases were selected as control patients. Baseline characteristics were similar between groups. Major morbidity was 27.6% and 34.5% in the rectal and colon group, respectively ( P = 0.516). Median disease‐free survival was 13.5 months in the rectal group and 13.6 months in the colon group ( P = 0.621). Two‐ and five‐year overall survival rates were 54%/32% in rectal cancer patients, and 61%/24% in colon cancer patients ( P = 0.987). Conclusions Cytoreduction and HIPEC in selected patients with rectal PM is feasible and provides similar outcomes as in colon cancer patients. Rectal PM should not be regarded a contra‐indication for cytoreduction and HIPEC in selected patients. J. Surg. Oncol. 2016;113:548–553 . © 2016 Wiley Periodicals, Inc.